Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986169 | 0.93 | BCL2L1 (0.46) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL2036814 | 0.83 | KMT2A (0.44) | TSHRALDH1A1SMN1; SMN2TDP1NPC1 | |
| SCHEMBL7561734 | 0.79 | KMO (0.45) | TSHRTP53CA1CA2CA12 | |
| Terephthalic Acid SCHEMBL27613025 | 0.76 | TSHR (0.80) | TSHRTP53CA1CA2SRD5A2 | |
| Terephthalic Acid SCHEMBL28261396 | 0.76 | TSHR (0.80) | TSHRTP53CA1CA2SRD5A2 | |
| Terephthalic Acid SCHEMBL448283 | 0.76 | TSHR (0.80) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL3984911 | 0.75 | KMT2A (0.36) | CA1CA2CA12CA3CA5A | |
| SCHEMBL76560 | 0.74 | LMNA (0.32) | ALDH1A1HTT | |
| Terephthalic Acid SCHEMBL20240891 | 0.73 | TSHR (0.75) | TSHRTP53CA1CA2SRD5A2 | |
| Terephthalic Acid SCHEMBL5907979 | 0.73 | TSHR (0.75) | TSHRTP53CA1CA2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384943-B2 | Substituted chroman derivatives | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20060223828-A1 | piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives; serotonin h5-HT1B receptor antagonist; regulate the synaptic concentration of serotonin by controlling the amount of 5-HT that is released; anxiolitic, antidepressant | BERG STEFAN | 2006-10-05 | — | — | US | disclosed |
| US-7056921-B2 | Substituted chroman derivatives | ASTRAZANECA AB (SE) | 2006-06-06 | — | — | US | disclosed |
| US-20040157857-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2004-08-12 | — | — | US | disclosed |
| US-6670359-B2 | Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders | ASTRAZENECA AB (SE) | 2003-12-30 | — | — | US | disclosed |
| EP-1025095-B1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030100556-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2003-05-29 | — | — | US | disclosed |
| EP-0888319-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-6479497-B1 | COMPOUNDS HAVING A SELECTIVE EFFECT AT A SUBGROUP OF 5-HYDROXYTRYPTAMINE RECEPTORS, DESIGNATED THE H5-HT1B RECEPTOR | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | disclosed |
| US-6410530-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-06-25 | — | — | US | disclosed |
| US-6124283-A | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | ASTRA AKTIEBOLAG (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-1025095-A1 | SUBSTITUTED CHROMAN DERIVATIVES | AstraZeneca AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999014212-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| EP-0888319-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034883-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100556-A1 | Substituted chroman derivatives | NR2C2, NR0B1, NR0B2 | TSHR 513/4885TP53 4311/4885CA1 3678/4885 |
| US-20060223828-A1 | piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives; serotonin h5-HT1B receptor antagonist; regulate the synaptic concentration of serotonin by controlling the amount of 5-HT that is released; anxiolitic, antidepressant | HTR2B, HTR2C, HTR2A | TSHR 243/4885TP53 4876/4885CA1 3525/4885 |
| US-20040157857-A1 | Substituted chroman derivatives | NR2C2, NR0B1, NR0B2 | TSHR 513/4885TP53 4311/4885CA1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.